Trials Sponsors Conditions Drugs Pricing

Conditions

Squamous Cell Carcinoma of the Oral Cavity

Keywords

oral cavitysquamous cell carcinomaresidual tumor DNAhead and neck surgery

Outcome Measures

Primary Outcomes (1)

Residual tumro DNA on operating bed
Proportion of patients with residual tumour DNA on the operating bed according to the presence or absence of adverse histological factors
during the surgery

Secondary Outcomes (1)

Survival without locoregional recurrence rate
24 months

Study Arms (1)

circulating tumor DNA detection on operating bed

EXPERIMENTAL

biological assessment on operating bed to detect residual circulating tumor DNA

Other: Circulating tumor DNA detection

Interventions

Circulating tumor DNA detectionOther

biological assessment on operating bed to detect residual circulating tumor DNA

circulating tumor DNA detection on operating bed

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Signed informed consent
Patient with T1 to T4 squamous cell carcinoma of the oral cavity, regardless of lymph node status (all N) M0, operable

Sponsors & Collaborators

Centre Henri Becquerel
Otherlead

Study Sites (2)

CHU Rouen

Rouen, 76000, France

Centre Henri Becquerel

Rouen, 76038, France

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsHead and Neck NeoplasmsNeoplasms by SiteNeoplasms, Squamous Cell

Study Officials

Lise-Marie Roussel, MD
Centre Henri Becquerel
PRINCIPAL INVESTIGATOR

Enrollment

31 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 29, 2023

First Posted

July 7, 2023

Study Start

January 8, 2024

Actual (reported)

Primary Completion

Contribution of Residual Tumour DNA Testing on the Surgical Bed

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

circulating tumor DNA detection on operating bed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

circulating tumor DNA detection on operating bed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations